Acute Gouty ArthritisPhase 2NCT07145229
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
A Phase 2 study testing ABP-745 Dose A, ABP-745 Dose B and Colchicine in people with Acute Gouty Arthritis and Gout Flare, run by Atom Therapeutics Co., Ltd at 38 sites in 3 countries.
Trial summary
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Acute Gouty Arthritis, Gout Flare, Gout Flares
- What is being tested?
- ABP-745 Dose A, ABP-745 Dose B and Colchicine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 479 participants
- Where
- 38 sitesin 3 countries
- Study dates
- 26 Aug 2025to 11 Aug 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects are eligible for the study if they meet all of the following Inclusion Criteria:
- Age 18-70 years old (inclusive), male or female.
- Body mass index (BMI)18-40 kg/m2 (inclusive).
- Medical history and current findings consistent with diagnosis of gouty arthritis.
- Subjects must have experienced 2 or more gout flares within 12 months prior to screening.
- Onset of an acute gout flare, within 6 months
- Patients receiving ULT agents (such as allopurinol, febuxostat, probenecid, etc.) must be on stable doses of these drugs prior to first dose of study drug (and remain on the same dose throughout the Treatment Period).
- Subjects agree to maintain a stable lifestyle (such as diet and exercise) during the study period.
Who cannot join
- Subjects are excluded from the study if one or more of the following criteria are met:
- Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.
- Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.
- Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.
- Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.
- Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.
Show all 16Show fewer
- Administration of muscle relaxants, central stimulants, barbiturates, etc. within 30 days prior to first dose of study drug or within 5 half-lives of the drug prior to the first dose of study drug, whichever is longer.
- Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout).
- Subjects with a current diagnosis or history of rheumatoid arthritis, psoriatic arthritis, evidence or suspicion of infectious/septic arthritis, calcium pyrophosphate (CPP) crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis or any other demyelinating disease, or; major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.); with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion or Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening
- Current anticoagulation therapy, thrombocytopenia, or diseases with a risk of thrombocytopenia, such as aplastic anemia, hypersplenism, or known hemorrhagic diseases like idiopathic thrombocytopenic purpura or hemophilia.
- History of malignancy within 5 years prior to screening, excluding localized cancers such as basal cell carcinoma.
- Presence of significant diseases, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160 or diastolic blood pressure ≥100 mmHg), congestive heart failure (New York Heart Association [NYHA] class III or above), uncontrolled type 1 or 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%). Inclusion will be determined by the Investigator based on the subject's specific condition.
- Women of childbearing potential as defined by Appendix 2.
- Experienced only no or mild gout-related pain prior to first dose of study drug.
- Use of gout flare prophylaxis (e.g., colchicine, NSAIDs, prednisone/methylprednisolone) at the time of randomization based on conversation with subject and self-reported.
- Corona Virus Disease (COVID) vaccination in the 4 weeks prior to randomization.
Trial locations and contacts
38 sites in 3 countries.
38 sites in 3 countries
China18 sites
Peking University Third hospital
Beijing, Beijing Municipality, 100000
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, 100000
Chengdu Fifth People's Hospital
Chengdu, Sichuan, 610000
Hangzhou First People's Hospital
Hangzhou, Zhejiang, 310000
Huai'an First People's Hospital
Huai'an, Jiangsu, 223000
Hebei Petro China Central Hospital
Langfang, Hebei, 065000
Linfen Central hospital
Linfen, Shanxi, 041000
The second affiliated hospital of guangxi medical university
Nanning, Guangxi, 530000
Pingxiang People's Hospital
Pingxiang, Jiangxi, 337000
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030000
Wenzhou People's Hospital
Wenzhou, Zhejiang, 325000
Wuhan UHospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000
Shaanxi Provincial People's Hospital
Xi’an, Shanxi, 710000
Xi'an Daxing Hospital
Xi’an, Shanxi, 710000
Xiangtan Central Hospital
Xiangtan, Hunan, 411100
Zaozhuang Municipal Hospital
Zaozhuang, Shandong, 277100
Xiangya Hospital Zhuzhou Central South University
Zhuzhou, Hunan, 412000
United States14 sites
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico, 87176
Northshore Research Associates
Alexandria, Louisiana, 71303
Premier Family Physicians
Austin, Texas, 78734
DelRicht Research
Baton Rouge, Louisiana, 70769
Exinia Research
Des Moines, Iowa, 50308
DelRicht Research Gulfport
Gulfport, Mississippi, 39501
Exinia Research
La Mesa, California, 91942
Interphase Clinical Trials
Lutherville, Maryland, 21093
West Clinical Research
Morehead City, North Carolina, 28557
Bioluminux Clinical Research
Naperville, Illinois, 60540
DelRicht Research
New Orleans, Louisiana, 70115
Evergreen Clinical Trial
Norcross, Georgia, 30003
Onyx Clinical Research
Peoria, Arizona, 61636
DelRicht Research
Tulsa, Oklahoma, 74133
Australia6 sites
Emeritus Sydney
Botany, New South Wales, 2019
Canopy Clinical Research Northern Beaches
Brookvale, New South Wales, 2100
Emeritus Melbourne
Camberwell, Victoria, 3124
Novatrials
Kotara, New South Wales, 2289
Genesis Research Services
Newcastle, New South Wales, 2019
Canopy Clinical Research Altona North
North Altona, Victoria, 3025
About this study
Official title: A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
- Conditions
- Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
- Being tested
- ABP-745 Dose A, ABP-745 Dose B, Colchicine, Placebo
- Keywords
- Gout, Gout Flare, Colchicine, Acute gout flare, ABP-745
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ABP-745 Dose ADrug
ABP-745 Dose A + Colchicine placebo - tablets (PO)
ABP-745 Dose BDrug
ABP-745 Dose B + Colchicine placebo - tablets (PO)
ColchicineDrug
ABP-745 placebo + Colchicine - tablets (PO)
PlaceboDrug
ABP-745 placebo + Colchicine placebo - tablets (PO)
| Study group | Role | What they receive |
|---|---|---|
| ABP-745 Dose A | Experimental | Not described Receives: Drug: ABP-745 Dose A |
| ABP-745 Dose B | Experimental | Not described Receives: Drug: ABP-745 Dose B |
| Colchicine | Active comparator | Not described Receives: Drug: Colchicine |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Visual Analog Scale (VAS) pain score of the target joint
Change from baseline in 0-100 mm VAS pain score of the target joint
Measured: 24 hours post the first dose of study drug
Secondary outcomes (2)
Change and percentage change from baseline in VAS pain score of the target joint
Measured: 2-8 days post the first dose of study drug
Incidence of treatment-emergent adverse events (Safety and Tolerability)
TEAEs and SAEs, and clinically significant changes in physical examination, vital signs, safety laboratory tests, and 12-lead ECG.
Measured: up to 14 days post the first dose of study drug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Aug 2025
- Study start26 Aug 2025
- Primary completion14 Jul 2026
- Study completion11 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Gouty ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 479 participants (actual)
Sponsor and investigators
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07145229
- Sponsor's protocol ID
- ABP-745-201
- Status last verified
- Oct 2026
- First submitted
- 13 Aug 2025
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare
- ClinicalTrials.gov ID
- NCT07145229
- Acronym / sponsor ID
- ABP-745-201
- Conditions
- Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
- Keywords
- Gout, Gout Flare, Colchicine, Acute gout flare, ABP-745
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 479 participants (actual)
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 26 Aug 2025 (actual)
- Primary completion
- 14 Jul 2026 (actual)
- Study completion
- 11 Aug 2026 (actual)
- First posted
- 28 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| ABP-745 Dose A | Experimental | Drug: ABP-745 Dose A |
| ABP-745 Dose B | Experimental | Drug: ABP-745 Dose B |
| Colchicine | Active comparator | Drug: Colchicine |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age 18-70 years old (inclusive), male or female.
- Body mass index (BMI)18-40 kg/m2 (inclusive).
- Medical history and current findings consistent with diagnosis of gouty arthritis.
- Subjects must have experienced 2 or more gout flares within 12 months prior to screening.
- Onset of an acute gout flare, within 6 months
Key exclusion criteria (16 listed)
- Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.
- Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.
- Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.
- Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.
- Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ABP-745 Dose AABP-745 Dose A + Colchicine placebo - tablets (PO) | Drug | ABP-745 Dose A |
| ABP-745 Dose BABP-745 Dose B + Colchicine placebo - tablets (PO) | Drug | ABP-745 Dose B |
| ColchicineABP-745 placebo + Colchicine - tablets (PO) | Drug | Colchicine |
| PlaceboABP-745 placebo + Colchicine placebo - tablets (PO) | Drug | Placebo |
Primary outcome
Change in Visual Analog Scale (VAS) pain score of the target joint
Time frame: 24 hours post the first dose of study drug
Change from baseline in 0-100 mm VAS pain score of the target joint
2 secondary outcomes
Change and percentage change from baseline in VAS pain score of the target joint
Time frame: 2-8 days post the first dose of study drug
Incidence of treatment-emergent adverse events (Safety and Tolerability)
Time frame: up to 14 days post the first dose of study drug
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Gouty Arthritis
Not yet recruitingPhase 2
A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis
Acute Gouty Arthritis
RecruitingPhase 2
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
Acute Gouty Arthritis
RecruitingPhase 2
Clinical Study of HRS-2129 for Acute Gouty Arthritis
Acute Gouty Arthritis
Not yet recruitingPhase 2
A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
Gout Arthritis
Not yet recruitingPhase 4
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time
Gout
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
38 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ABP-745 Dose A, ABP-745 Dose B and Colchicine in people with Acute Gouty Arthritis and Gout Flare, run by Atom Therapeutics Co., Ltd at 38 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 38 sites in China, United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Visual Analog Scale (VAS) pain score of the target joint (time frame: 24 hours post the first dose of study drug). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.